Propofol/Dexmedetomidine Versus Desflurane Effects on Post Hepatectomy Hepatocellular Injury

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05246371

Enrollment

Registered

2022-02-18

Start date

2021-06-01

Completion date

2023-11-30

Last updated

2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatectomy

Brief summary

This study will compare the effects of propofol/dexmedetomidine versus desflurane for maintenance of general anesthesia on hepatocellular injury in patients undergoing partial hepatectomy.

Detailed description

Postoperative impairment of liver function is common after hepatectomy. It may be caused by surgical trauma, loss of hepatic mass, stress response, hepatic oxygen deprivation, infection and drug toxicity. Anesthetic agents used in general anesthesia for liver surgery have a big effect on hepatic blood flow, oxygen delivery and liver function This study will compare the effects of propofol/dexmedetomidine versus desflurane for maintenance of general anesthesia on hepatocellular injury in patients undergoing partial hepatectomy.

Interventions

DRUGPropofol, dexmedetomidine

Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.

DRUGDesflurane

Patients will receive maintenance of general anesthesia by desflurane.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Patients American Society of Anesthesiologists physical status (ASA) I to II. 2. Patients Child Pugh classification A to B. 3. Both sexes. 4. Aged between 18 years and 70 years 5. Scheduled for more than 1 segment hepatectomy.

Exclusion criteria

1. Patients with Child Pugh classification C. 2. Patients younger than18 years old or older than 70 years old 3. Patients performed additional ablation therapies (cryosurgery or radiofrequency ablation). 4. Prior liver resection for donation. 5. Scheduled resection not requiring inflow occlusion (Pringle's maneuver). 6. Hypersensitivity to any of the used drugs.

Design outcomes

Primary

Measure	Time frame	Description
aspartate aminotransferase (AST)	1 week	aspartate aminotransferase (AST)
alanine aminotransferase (ALT)	1 week	alanine aminotransferase (ALT)
bilirubin	1 week	bilirubin
albumin	1 week	albumin
prothrombin time	1 week	prothrombin time
INR	1 week	INR

Countries

Egypt

Contacts

Primary Contactola Lashin, Master

Ola.lashin@med.asu.edu.eg00201026034100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026